To follow me click the "Follow" button! (Easy right?)
Kumquat Research is a college student and fund manager who has been investing for 4 years. He writes mostly about the technology sector and about event-driven and momentum opportunities across various industries and sectors. He is currently studying for degrees in both finance and computer science at the University of Maryland. Some of his interests include technology, programming, drumming, video games (developing and playing) and astronomy. Articles written and comments posted by Kumquat Research are NOT financial or investment advice, and only express his opinion. Do your own due diligence!
MD, MBA (NYU-Stern, Finance specialization). Founder: Vasuda Healthcare Analytics, premium research service covering emerging biotech/ pharma companies (in partnership with Seeking Alpha).
Licensed Investment professional. Buy-side equity research analyst covering mainly small-cap, emerging pharma/ biotech companies. M.D. with over 18 years of clinical experience (in the U.S. and India), still retaining full medical license in India. M.B.A. with finance and financial markets specialization from New York University Stern School of Business.
Expert in picking healthcare-related investments, especially biotechnology and pharmaceuticals (focus on small, emerging companies). Investments are selected based on detailed due diligence, including proprietary DCF valuation models. Value investor with long-term horizon. Founder, managing principal of Vasuda Capital Management, healthcare focused investment management firm, vasudacapitalmanagement.com.
Registered Investment Advisor in Massachusetts. The firm also operates a private pooled investment partnership, Vasuda Life Sciences Fund.
Also started and continue to sponsor Vasuda Global Orphan/ Rare disease biotechnology index, the first global equity index covering rare/orphan disease sector. Index quotes are available on bloomberg/reuters terminals.
I am a Ph.D. level scientist at a major pharmaceutical company. Previously I was an NIH Cancer Postdoctoral fellow at UPENN. Through my extensive research background, I am able to quickly decipher clinical information and act on it. I specialize in analyzing and trading biotech/healthcare stocks both long and short. I maintain a few core positions and trade clinical events based on extensive research to realize large percentage gains. I am open to opportunities in consulting for financial firms or local advisors. Please contact me if you are interested.
NYC-based investment professional. Focus on value investing and growth at reasonable price within the context of long/short equity, with a bias toward long-term holding periods.
I will no longer be active directly in article comments streams. However, if you wish to contact directly, you can PM me on-site or send messages to this address: LSI.email@example.com
I am professional with many years of experience in the pharmaceutical, biotech and device industry covering all functional areas from R&D to product commercialization. I write on Seeking Alpha regarding topics that I find interesting and focus on in depth financial and scientific research.
Data Center Knowledge - Contributor: writing about data centers REITs -- a new and growing asset class -- attempting to bridge the gap between technology & traditional REIT investors.
Researching and writing at the corner of Main St. & Wall St. where real estate often intersects with trends in: technology, ecommerce, office/industrial, healthcare, cloud computing, energy infrastructure & green initiatives.
Recently covered breaking news and actionable ideas REIT ideas for Benzinga "REIT Beat," now Contributor/Sr. REIT Expert. Select articles featured on Investopedia.com, Seeking Alpha, and published on Yahoo! Finance, Google, MSN, Finviz and many other financial portals. Recent Select Freelance contributor for Motley Fool, writing about REITs and real estate topics for the Financial Bureau.
I have over 25 years of experience as a: developer of institutional quality office and industrial facilities, general contractor, homebuilder, managing general partner for private limited partnerships, and have performed consulting and transactional real estate services for others, including entitlements for planned commercial/office/industrial developments.
Past job experience included: V.P. of Energy Services for a Florida based Mechanical Contracting company, which subsequently was acquired by EMCOR (NYSE: EME). Responsibilities included development and "financial engineering" of projects to reduce energy consumption and total cost of ownership solutions, partnered with the two major Florida electric utilities, and private companies, (including Enron Energy Services!).
Education: UCLA - BA Economics, including graduate coursework in Real Estate Finance.
Masters Degree from St. Thomas University - Miami, FL
Prescience Point's founders have over 25 years of combined Wall Street experience, and a significant track-record of successful short recommendations.
The sole focus of our company is to conduct comprehensive fundamental research, and uncover companies that are engaging in fraudulent or misleading business practices. We partner with leading hedge funds, private investigators, accountants, lawyers and industry experts to conduct our research process. We take an activist role to communicate our findings to regulators, shareholders, and other public constituents.
Our firm was founded on the belief that investors deserve full and complete honesty, transparency and accountability from corporations they invest with. We set high expectations and standards for our research process and opinions, and strive to achieve the respect from our readers for our integrity, intellectual honesty, analytical rigor, and accuracy of our conclusions.
A veteran of the pharma industry. Specializing in the analysis of small pharma companies with a focus on the pipeline and opportunities for licensing or major deals with large pharma. Financial analysis including burn rate, venture capital funding, and cash flow.
I seek to liberate investors from the chains of borrowed opinions by teaching metric awareness that leads to the formation of your own opinions. I am a retail investor that gathers, processes and analyzes significantly more data than average. I share that data in my articles. I let the data do the talking. I am only taking dictation as the data tells its message.
I am a part time investor focused on building my family's wealth incrementally over the long term by investing in companies that are well positioned to benefit from important macroeconomic themes. I have a passion for research and hold a M.S from the University of Pennsylvania. I have been an active investor for well over a decade and consider the understanding of global markets and major economic themes as one of my life's passions. I believe that investors can build wealth over the long term by ignoring short term market fluctuations and market "noise" to focus on global economic themes and fundamental company performance.
Retired, late 50's
Hold CFP designation. Passed CFP exam Nov 2000
Author of "IRA: A Quck Reference Guide". Available on Amazon as an e-book.
Author of "Retirement Investing for INCOME ONLY: How to invest for relaible income in Retirement ONLY from Dividends"
I joined Seeking Alpha as a Senior Editor in June 2012. Currently, I manage the Dividends, Income & Retirement and Expert Insight platforms. D&I focuses on income investment strategies and dividend investment-focused content for investors from the accumulation stage to retirement. The purpose of Expert Insight is to expand and elevate the quality of Seeking Alpha's content by including articles from an industry insider's point of view, designed to help investors make more informed decisions as they consider specific sectors and trends within those sectors for their investing strategies, e.g., utilities or technology. Expert Insight articles offer more of a macro, 30,000-foot-view that goes beyond investment analysis or stock recommendations.
I also curate the Dividends & Income Digest, a bi-weekly publication that takes a look at a question that is compelling and relevant to the community, showcases the responses of DI thought leaders, and serves as a round-up of top DI articles.
I hope to continue to discover new voices and thought leaders through insightful articles and conversations in the comments threads. My goal is to draw a large, diverse audience to Seeking Alpha, and make our community THE go-to place to participate in investing research and exchange lucrative, unique, exciting investing knowledge and ideas. I'm always looking for new ideas and contributors, so please feel free to reach out to me. I'm eager to hear your thoughts and discover how we can work together to make Seeking Alpha the best site for investors on the web.
Zach is a biotech investor with PhD training in Biochemistry and Molecular Biology. In real life, he is a scientific writer specializing in continuing medical education. He hopes to provide a crucial piece of total due diligence as well as interesting insight into clinical findings that may impact readers' portfolios and lives.
Ever feel like trading is like rolling dice? In a way, it is, because every mathematical model of the market includes a stochastic aspect. But I believe we can load the dice in our favor through the use of statistics. Understanding both the stock market and each individual stock as a sort of random process with its own characteristics allows us to more accurately predict what it will do in the future. Coupling statistics with fundamental analysis, I have the goal of revealing to you the hidden patterns within stocks so that you may do what you wish with that information.
Former broker, now an independent analyst/writer on Seeking Alpha and founder and editor of the Growth Stock Forum. Focusing on small-cap, mid-cap and biotech stocks. Looking for substantial sales and earnings growth potential and seeking the best risk-adjusted returns from my stock selection. Taking advantage of medium to long-term momentum.
My articles represent my personal opinion and analysis and should not be regarded as investment advice in any way. Readers and subscribers should do their own due diligence and/or consult their financial advisor before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal.
Exclusive research: http://seekingalpha.com/author/oneil-trader/research
Principal En-lightener - Purveyor of Darkness.
And Now - The Gift...
Stupid is as stupid does - Forrest Gump;
You can't fix stupid, no pill for it, it's fo'ever - Ron White ;
There are idiots, look around - Larry Summers ;
To avoid the pernicious global plague of stupidity, drink the Kool-Aid and become one of the innoculati. The Kool-Aid is available at [VIRUS REMOVED BY ECHELON UNDER ORDER OF PATRIOT ACT II ... transmission terminated]
Medical doctor and independant investor. My investment strategy is to utilize my medical education, combined with market technical and fundamental analysis, to find undervalued biopharmaceutical investments which have a high likelihood of increasing in value over a specified time period. I look for companies whose stocks have recently dropped due to technical factors, misunderstood data or undervalued market opportunity among other factors.
Lawrence is the Managing Director of Fuller Asset Management. He has 20+ years of experience managing investment portfolios and serving the needs of individual clients. He began his career as a Financial Consultant in 1993 with Merrill Lynch. He worked for First Union Brokerage, Morgan Stanley and ING in the same capacity before realizing his long-term goal of complete independence. He graduated from the University of North Carolina at Chapel Hill with a B.A. in Political Science in 1992.
Long-only value investor running a fund for accredited investors, and a Marketplace subscription for objective buyside research. Pseudonymous to protect my IR access but if you send me your email address and show me your LinkedIn, I'll show you mine. I'm not like anyone you've ever met and am not doing this for the traditional reasons. I’m always up for a conversation with anyone interested in value investing or mental models.
My Marketplace subscription service, called “Outsourced Analyst,” provides small-mid-sized funds, family offices, or high-net-worth investors the workflow of an analyst for a hundredth of the price. I write objective coverage of high-quality, underfollowed small-caps that I'm working on / following. Subscribers also have early (sometimes exclusive) access to writeups of some of my best ideas like those I've posted on LQDT, CRAI, FC, LGIH, BOOM, CSWI, and so on. Bonus material is thought pieces - I place a lot of emphasis on learning and getting better - so if/when I make mistakes, I'll write up postmortems with what I learned, and maybe they'll help you as well... Membership will be limited to the first 250 subscribers.
Seeking Alpha T&C requires me to disclose that I'm a registered investment advisor; regulations require me to reiterate that nothing I say is investment advice - it's just my Monday-morning-quarterback opinion for your entertainment and amusement. Always do your own due diligence, consider your own financial position, and consult your preferred financial professional before making any investment decision.
After spending a dozen years making a big name for herself as a highly respected investigative reporter in the financial arena, Melissa Davis took a chance on her longtime dream in 2015 by becoming her own boss so that she could pour even more time and energy into uncovering the truth about suspicious public companies by conducting the deepest research of her award-winning career. At that point, Ms. Davis had already established herself as a fearless journalist with an impressive talent for exposing corporate fraud. Most recently, she served as the founding editor of TheStreetSweeper, a financial news website dedicated to warning investors about risky stocks that she essentially built from scratch. Under her leadership, TheStreetSweeper soon earned steady applause from some of the biggest names in the business and continued to flourish for years. Prior to launching that well-known website, Ms. Davis spent seven years on the staff of TheStreet.com -- an even more prominent financial outlet founded by "Mad Money" host Jim Cramer -- where she quickly rose to become one of the leading investigative reporters on a large and impressive editorial team. Already the recipient of numerous awards by the time that TheStreet.com hired her away from the largest newspaper in her home state, Ms. Davis went on to land a national prize for enterprise reporting from the Society of American Business Editors and Writers (SABEW) by the time that her tenure there came to an end. Today, she spends her days (and, when necessary, plenty of late nights) trying to do what she has always done the best even better: revealing the dirty secrets about publicly traded companies that investors desperately need -- and inherently deserve -- to know! (She also smothers her adorable granddaughter -- the other great love of her life -- with plenty of hugs and kisses at every available chance.)
Nicholas Vardy is editor of The Global Guru, a weekly free e-letter; the monthly Alpha Investor Letter; and two weekly trading services, Bull Market Alert and Alpha Algorithm for Washington DC-based Eagle Financial Publications. He has been a columnist for TheStreet.com and currently writes for Dow Jones Markewatch. He has been cited in Wall Street Journal, Financial Times, Forbes, Investors Business Daily,Yahoo! Finance, theStreet.com, and MSN Money Central. He has appeared on CNBC Asia, Fox Business News and CNN International. Vardy is a graduate of Stanford and Harvard Law School, a former Fulbright scholar, and a Chartered Financial Analyst (CFA).
I am a former engineer in topography (ESGT Paris 80) and specialized later in metrology or very precise measurement (CERN). I was interested in quantum metrology for a while...
I live mostly between California (Santa Monica), Provence-Cote d'Azur (Where my children and grandchildren live) and Sweden (South West Skåne) with my loving wife.
I am managing (investment manager) a large and old private family fund and trade personally a medium-size portfolio for over 25 years
“Logic will get you from A to B. Imagination will take you everywhere.” Einstein.
Vahan Janjigian is Chief Investment Officer at Greenwich Wealth Management, LLC, an SEC registered investment advisor. He previously served as Chief Investment Strategist at Forbes Media, LLC. He has served on the finance faculties of several universities, including Baruch College, Boston College, Northeastern University, and University of Delaware.
Research Affiliates, LLC, is a global leader in smart beta and asset allocation. Dedicated to creating value for investors, we seek to have a profound impact on the global investment community through our insights and products.
Our investment strategies are built on a strong research base and are led by Rob Arnott and Chris Brightman. We deliver solutions in partnership with some of the world’s leading financial institutions, through their offerings of mutual funds, ETFs, separately managed accounts, and/or commingled accounts.
Research Affiliates was founded in 2002 and is based in Newport Beach, California.
Our Mission Research Affiliates is committed to being the preeminent source of insights and products that transform the global investment community for the benefit of investors.